Sometimes pharma companies bend the rules. And increasingly, they're getting caught, writes FiercePharma Editor Maureen Martino. After Novartis' recent $422.5 million settlement with the U.S. Attorney's office and reader requests, FiercePharma looked back at other Department of Justice and government fines levied against Big Pharma for improper marketing and other infractions. Those fines range from a relatively light slap on the wrists to multi-billion dollar charges in addition to criminal penalties. Special Report